<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234585</url>
  </required_header>
  <id_info>
    <org_study_id>xMUO-01</org_study_id>
    <nct_id>NCT00234585</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Study Comparing Renal Artery Stenting (RESIST)With/Without Distal Protection</brief_title>
  <official_title>A Prospective Randomized Multicenter Study Comparing the Safety and Efficacy of Renal Artery Stenting With/Without Distal Protection Device (AngioGuard) and With/Without the Use of a Platelet Aggregator Inhibitor (Abciximab-Reopro) (RESIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toledo Health Science Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toledo Health Science Campus</source>
  <brief_summary>
    <textblock>
      This study is designed to demonstrate the safety and efficacy of using a protective&#xD;
      device/drug to prevent renal injury during renal artery stenting and to assess whether the&#xD;
      preventative effects are measurable and if there is a differential treatment effect for&#xD;
      either device alone or in combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to demonstrate the safety and efficacy of using protective device/drug&#xD;
      to prevent renal injury during renal artery stenting (RAS) and to assess whether the&#xD;
      preventative effects are measurable, and if there is a differential treatment effect for&#xD;
      either device alone or in combination.&#xD;
&#xD;
      Specific goals of the study include:&#xD;
&#xD;
        -  To establish device and drug safety&#xD;
&#xD;
        -  To identify appropriate markers for renal injury&#xD;
&#xD;
        -  To measure effectiveness of drug and device&#xD;
&#xD;
        -  To enable the design of FDA efficacy trials for renal artery stenting inclusive of&#xD;
           device and or drug&#xD;
&#xD;
      The study will address the four following hypotheses:&#xD;
&#xD;
        -  AngioGuard™ distal protection device provides significant protection from&#xD;
           atheroembolization during RAS procedures as measured by affected kidney GFR at 1 month&#xD;
           after the procedure.&#xD;
&#xD;
        -  Abciximab (ReoPro) offers protection against platelet aggregation and embolization as&#xD;
           measured by affected kidney GFR at 1 month after the procedure.&#xD;
&#xD;
        -  AngioGuard™ and Abciximab are safe, alone and in combination.&#xD;
&#xD;
        -  Is there an interaction effect between AngioGuard™ and ReoPro for efficacy and safety?&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular Filtration Rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
  </primary_outcome>
  <enrollment>100</enrollment>
  <condition>Renal Artery Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal Artery Stent with Protective Device/Drug</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Any one or more of the following:&#xD;
&#xD;
        Meet Angiographic criteria plus&#xD;
&#xD;
          -  Systemic hypertension at baseline, or a history of hypertension&#xD;
&#xD;
          -  Congestive heart failure at baseline, or a history of CHF&#xD;
&#xD;
          -  Renal insufficiency at baseline, or a history of renal insufficiency&#xD;
&#xD;
          -  Angina, or a history of angina&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 18 years old&#xD;
&#xD;
          -  Contraindications to device/drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Cooper, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Ohio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Ohio</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>October 5, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2005</study_first_posted>
  <last_update_submitted>December 9, 2014</last_update_submitted>
  <last_update_submitted_qc>December 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Artery Obstruction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

